BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Steiner CA, Rodansky ES, Johnson LA, Berinstein JA, Cushing KC, Huang S, Spence JR, Higgins PDR. AXL Is a Potential Target for the Treatment of Intestinal Fibrosis. Inflamm Bowel Dis 2021;27:303-16. [PMID: 32676663 DOI: 10.1093/ibd/izaa169] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
Number Citing Articles
1 Santacroce G, Lenti MV, Di Sabatino A. Therapeutic Targeting of Intestinal Fibrosis in Crohn's Disease. Cells 2022;11:429. [PMID: 35159238 DOI: 10.3390/cells11030429] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Pivetta E, Capuano A, Vescovo M, Scanziani E, Cappelleri A, Vinciguerra GLR, Vecchione A, Doliana R, Mongiat M, Spessotto P. EMILIN-1 deficiency promotes chronic inflammatory disease through TGFβ signaling alteration and impairment of the gC1q/α4β1 integrin interaction. Matrix Biol 2022:S0945-053X(22)00085-3. [PMID: 35764213 DOI: 10.1016/j.matbio.2022.06.005] [Reference Citation Analysis]
3 Zhang Y, Wang Y, Ding J, Liu P. Efferocytosis in multisystem diseases (Review). Mol Med Rep 2022;25:13. [PMID: 34779503 DOI: 10.3892/mmr.2021.12529] [Reference Citation Analysis]
4 Estrada HQ, Patel S, Rabizadeh S, Casero D, Targan SR, Barrett RJ. Development of a Personalized Intestinal Fibrosis Model Using Human Intestinal Organoids Derived From Induced Pluripotent Stem Cells. Inflamm Bowel Dis 2021:izab292. [PMID: 34918082 DOI: 10.1093/ibd/izab292] [Reference Citation Analysis]
5 Abdulla M, Chew TS. Molecular targets and the use of biologics in the management of small bowel fibrosis in inflammatory bowel disease. Curr Opin Gastroenterol 2021;37:275-83. [PMID: 33769380 DOI: 10.1097/MOG.0000000000000729] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Sleiman J, El Ouali S, Qazi T, Cohen B, Steele SR, Baker ME, Rieder F. Prevention and Treatment of Stricturing Crohn's Disease - Perspectives and Challenges. Expert Rev Gastroenterol Hepatol 2021;15:401-11. [PMID: 33225766 DOI: 10.1080/17474124.2021.1854732] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
7 Wang J, Lin S, Brown JM, van Wagoner D, Fiocchi C, Rieder F. Novel mechanisms and clinical trial endpoints in intestinal fibrosis. Immunol Rev 2021;302:211-27. [PMID: 33993489 DOI: 10.1111/imr.12974] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
8 Steiner CA, Rieder F. No Longer Stretching Credibility: Mechanical Force Meets Inflammation in Experimental Intestinal Stenosis. Dig Dis Sci 2021. [PMID: 34350517 DOI: 10.1007/s10620-021-07170-4] [Reference Citation Analysis]
9 Rakowsky S, Papamichael K, Cheifetz AS. Choosing the right biologic for complications of inflammatory bowel disease. Expert Review of Gastroenterology & Hepatology. [DOI: 10.1080/17474124.2022.2036122] [Reference Citation Analysis]
10 Yu Q, Kilik U, Holloway EM, Tsai YH, Harmel C, Wu A, Wu JH, Czerwinski M, Childs CJ, He Z, Capeling MM, Huang S, Glass IA, Higgins PDR, Treutlein B, Spence JR, Camp JG. Charting human development using a multi-endodermal organ atlas and organoid models. Cell 2021;184:3281-3298.e22. [PMID: 34019796 DOI: 10.1016/j.cell.2021.04.028] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
11 D'Alessio S, Ungaro F, Noviello D, Lovisa S, Peyrin-Biroulet L, Danese S. Revisiting fibrosis in inflammatory bowel disease: the gut thickens. Nat Rev Gastroenterol Hepatol 2021. [PMID: 34876680 DOI: 10.1038/s41575-021-00543-0] [Reference Citation Analysis]
12 Kandilogiannakis L, Filidou E, Drygiannakis I, Tarapatzi G, Didaskalou S, Koffa M, Arvanitidis K, Bamias G, Valatas V, Paspaliaris V, Kolios G. Development of a Human Intestinal Organoid Model for In Vitro Studies on Gut Inflammation and Fibrosis. Stem Cells Int 2021;2021:9929461. [PMID: 34354753 DOI: 10.1155/2021/9929461] [Reference Citation Analysis]
13 Caballol B, Gudiño V, Panes J, Salas A. Ulcerative colitis: shedding light on emerging agents and strategies in preclinical and early clinical development. Expert Opin Investig Drugs 2021;:1-16. [PMID: 34365869 DOI: 10.1080/13543784.2021.1965122] [Reference Citation Analysis]